Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First in Human Dose Escalation Study of AU409 in Patients With Advanced Primary Liver Cancers or Advanced Solid Tumor With Liver Predominant Metastatic Disease

NCT05791448 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT05791448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05791448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First in Human Dose Escalation Study of AU409 in Patients With Advanced Primary Liver Cancers or Advanced Solid Tumor With Liver Predominant Metastatic Disease
Lead sponsor
University of Southern California
Phase
Phase 1
Overall status
Suspended
Start date
March 29, 2023
Completion date
March 29, 2028
Enrollment
36 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cholangiocarcinoma, advanced hepatocellular carcinoma, advanced malignant solid neoplasm, metastatic malignant neoplasm in the liver, refractory malignant solid neoplasm, stage iii hepatocellular carcinoma ajcc v8, stage iv hepatocellular carcinoma ajcc v8